32 min listen
CGTs for HIV Suppression with Addimmune's Dr. Marcus Conant
CGTs for HIV Suppression with Addimmune's Dr. Marcus Conant
ratings:
Length:
19 minutes
Released:
May 9, 2024
Format:
Podcast episode
Description
Dr. Marcus Conant is CMO at Addimmune, a biotech startup developing a cell therapy for HIV that spun out of cell and gene therapy biotech American Gene Technologies (AGT). He spent his career on the front lines of HIV treatment and research and remains an advocate for the HIV patient. He formed the Kaposi’s Sarcoma Research & Education Foundation in 1982, which later became the San Francisco AIDS Foundation. On this episode, Dr. Conant shares they why behind cell and gene therapy to treat HIV, and he explains Addimmune’s lead asset, AGT103-T, which is designed to provide broad protection using silencing RNA to inhibit binding/entry of the virus, halt replication, and prevent escape.
Released:
May 9, 2024
Format:
Podcast episode
Titles in the series (77)
Automating Processes to Scale CGT Manufacturing with PA Consulting's Paolo Siciliano by Cell & Gene: The Podcast